HomeQuanterix Corporation

Quanterix Corporation

Quanterix Extends Oncology Footprint with Accelerated Launch of Next Gen SP-X™ Platform and CorPlex™ Validated 10-Plex

1/10/19: Company reports the new instrument platform and highly validated CorPlex assays promise to revolutionize oncology research and drug development. The progress made since the early access program was initiated in early November 2018 with select industry leaders has validated the performance and promise of the technology, resulting in an accelerated timeline for full launch. The company is now taking orders for shipping by April 1.